Cardlytics (CDLX) Tops Q1 EPS by 15c, provides guidance

Cardlytics (NASDAQ: CDLX) reported Q1 EPS of ($0.11), $0.15 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $34.3 million versus the consensus estimate of $48.7 million.

GUIDANCE:

Cardlytics sees Q2 2026 revenue of $35-40 million, versus the consensus of $38.659 million.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• KeyBanc Upgrades Acadia Realty Trust (AKR) to Overweight
• Infleqtion raises Q2 revenue to $13.5M after contract restatement